Montané Jaime Lazara Karelia, Paul Jeffrey, Lalla Anthony, Legall George, Gaedigk Andrea
Pharmacology Unit, Department of Paraclinical Sciences, Faculty of Medical Sciences, The University of The West Indies, St Augustine, Trinidad & Tobago.
JPharm Consulting, Evanston, IL 60201, USA.
Pharmacogenomics. 2018 Feb;19(3):197-212. doi: 10.2217/pgs-2017-0142. Epub 2018 Jan 12.
This study aimed to assess the impact of CYP2D6 and CYP2C19 variation on venlafaxine (VEN) at steady state in patients from Trinidad and Tobago of Indian and African descent with major depressive disorder.
PATIENTS & METHODS: Patients were phenotyped with dextromethorphan, genotyped for CYP2D6 and CYP2C19, and metabolic ratios for VEN obtained at 2-week intervals.
Of 61 patients, 55 were genotyped and phenotyped and 47 completed 8 weeks of VEN treatment. The majority of patients had metabolic ratios for VEN that were consistent with those for dextromethorphan and genotype-predicted phenotype using activity scores. One subject presented with a novel no-function allele, CYP2D6*99. No correlations were observed with CYP2C19 genotype.
CYP2D6 genotype analysis provides valuable information to individualize drug therapy with VEN.
本研究旨在评估CYP2D6和CYP2C19基因变异对特立尼达和多巴哥患有重度抑郁症的印度裔和非裔患者在稳态时文拉法辛（VEN）的影响。
患者用右美沙芬进行表型分析，对CYP2D6和CYP2C19进行基因分型，并每隔2周获取VEN的代谢率。
61例患者中，55例进行了基因分型和表型分析，47例完成了8周的VEN治疗。大多数患者VEN的代谢率与右美沙芬的代谢率一致，且使用活性评分时与基因型预测的表型一致。一名受试者出现了一种新的无功能等位基因CYP2D6*99。未观察到与CYP2C19基因型的相关性。
CYP2D6基因分型分析为VEN的个体化药物治疗提供了有价值的信息。
